TY - JOUR
T1 - A risk score for identifying patients at a low risk of bacterial meningitis amongst adults with cerebrospinal fluid leucocytosis and a negative gram stain result
T2 - a derivation and validation study
AU - van Soest, Thijs M
AU - Horst, Liora Ter
AU - Chekrouni, Nora
AU - Bijlsma, Merijn W
AU - Brouwer, Matthijs C
AU - Portillo, Daniela Urueta
AU - van de Beek, Diederik
AU - Hasbun, Rodrigo
N1 - Funding Information: This work was previously presented at the Amsterdam Neurosciences Annual Meeting (online, 2021), the European Congress of Clinical Microbiology & Infectious Diseases (Lisbon, 2022), and the European Academy of Neurology congress (Vienna, 2022). Funding Information: RH receives research support and personal fees from Biofire®. The remaining authors declare no conflicts of interests. This work was supported by the Netherlands Organization for Health Research and Development (ZonMw; NWO-Vidi Grant [grant number 917.17.308 to MCB], NWO-Vici-Grant [grant number 918.19.627 to DvdB]); the Academic Medical Centre (AMC Fellowship to DvdB); the European Research Council (ERC Consolidator grant to MCB, ERC Starting grant to D.B.); Stichting de Merel (seed grant to MCB); Dr. Jan Meerwaldt Foundation (travel grant to LtH); Remmert Adriaan Laan Foundation (travel grant to LtH); and the Royal Netherlands Academy of Arts & Sciences (KNAW Van Leersum Grant to LtH). Publisher Copyright: © 2022 European Society of Clinical Microbiology and Infectious Diseases
PY - 2022/10/8
Y1 - 2022/10/8
N2 - Objectives: We aimed to derive and validate a risk score to differentiate patients with bacterial meningitis from those with viral meningitis or encephalitis amongst patients presenting with cerebrospinal fluid (CSF) leucocytosis and a negative Gram staining result. Methods: We included adults with bacterial and viral meningitis or encephalitis presenting with CSF leukocyte counts of >10 per mm3 and a negative Gram staining result from cohorts in Houston, Texas (2004–2019), and the Netherlands (2012–2021). Derivation and the first validation were performed in the American patients and further validation in the Dutch patients. Results: Derivation was performed in 109 American patients with bacterial meningitis (median age, 56 years; interquartile range [IQR], 46–66 years; 46% women) and 194 with viral meningitis or encephalitis (median age, 46 years; IQR, 33–60 years; 53% women). Serum leukocyte counts of >10.0 × 109/L, CSF leukocyte counts of >2000 per mm3, granulocyte counts of >1180 per mm3, protein levels of >2.2 g/L, glucose levels of <1.9 mmol/L and fever on admission were included in the risk score, which was dichotomized into ‘low risk’ (0 present) and ‘high risk’ (>0 present). The first validation showed a sensitivity of 100% (95% CI, 96.6–100) and specificity of 34.0% (95% CI, 27.4–41.2). Further validation in 262 Dutch patients with bacterial meningitis (median age, 57 years; IQR 44–70 years; 45% women) and 68 with viral meningitis (median age, 34 years; IQR, 28–45 years; 60% women) showed a sensitivity of 99.6% (95% CI, 97.9–100) and specificity of 41.2% (95% CI, 29.4–53.7). Conclusions: Our risk score may be able to rule out bacterial meningitis amongst patients presenting with CSF leucocytosis and a negative Gram staining result. However, it needs prospective testing prior to clinical implementation.
AB - Objectives: We aimed to derive and validate a risk score to differentiate patients with bacterial meningitis from those with viral meningitis or encephalitis amongst patients presenting with cerebrospinal fluid (CSF) leucocytosis and a negative Gram staining result. Methods: We included adults with bacterial and viral meningitis or encephalitis presenting with CSF leukocyte counts of >10 per mm3 and a negative Gram staining result from cohorts in Houston, Texas (2004–2019), and the Netherlands (2012–2021). Derivation and the first validation were performed in the American patients and further validation in the Dutch patients. Results: Derivation was performed in 109 American patients with bacterial meningitis (median age, 56 years; interquartile range [IQR], 46–66 years; 46% women) and 194 with viral meningitis or encephalitis (median age, 46 years; IQR, 33–60 years; 53% women). Serum leukocyte counts of >10.0 × 109/L, CSF leukocyte counts of >2000 per mm3, granulocyte counts of >1180 per mm3, protein levels of >2.2 g/L, glucose levels of <1.9 mmol/L and fever on admission were included in the risk score, which was dichotomized into ‘low risk’ (0 present) and ‘high risk’ (>0 present). The first validation showed a sensitivity of 100% (95% CI, 96.6–100) and specificity of 34.0% (95% CI, 27.4–41.2). Further validation in 262 Dutch patients with bacterial meningitis (median age, 57 years; IQR 44–70 years; 45% women) and 68 with viral meningitis (median age, 34 years; IQR, 28–45 years; 60% women) showed a sensitivity of 99.6% (95% CI, 97.9–100) and specificity of 41.2% (95% CI, 29.4–53.7). Conclusions: Our risk score may be able to rule out bacterial meningitis amongst patients presenting with CSF leucocytosis and a negative Gram staining result. However, it needs prospective testing prior to clinical implementation.
KW - Antibiotic use
KW - Community-acquired bacterial meningitis
KW - Risk score
KW - Viral encephalitis
KW - Viral meningitis
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85140965244&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36220627
UR - http://www.scopus.com/inward/record.url?scp=85140965244&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.cmi.2022.10.001
DO - https://doi.org/10.1016/j.cmi.2022.10.001
M3 - Article
C2 - 36220627
SN - 1198-743X
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
ER -